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Abstract
Background: Obstructive sleep apnea is a relatively common disorder that can lead to lost productivity and
cardiovascular disease. The form of positive airway treatment that should be offered is unclear.
Methods: MEDLINE and the Cochrane Central Trials registry were searched for English language randomized
controlled trials comparing auto-titrating positive airway pressure (APAP) with continuous positive airway pressure
(CPAP) in adults with obstructive sleep apnea (inception through 9/2010). Six researchers extracted information on
study design, potential bias, patient characteristics, interventions and outcomes. Data for each study were extracted
by one reviewer and confirmed by another. Random effects model meta-analyses were performed for selected
outcomes.
Results: Twenty-four randomized controlled trials met the inclusion criteria. In individual studies, APAP and fixed
CPAP resulted in similar changes from baseline in the apnea-hypopnea index, most other sleep study measures
and quality of life. By meta-analysis, APAP improved compliance by 11 minutes per night (95% CI, 3 to 19 minutes)
and reduced sleepiness as measured by the Epworth Sleepiness Scale by 0.5 points (95% CI, 0.8 to 0.2 point
reduction) compared with fixed CPAP. Fixed CPAP improved minimum oxygen saturation by 1.3% more than APAP
(95% CI, 0.4 to 2.2%). Studies had relatively short follow-up and generally excluded patients with significant
comorbidities. No study reported on objective clinical outcomes.
Conclusions: Statistically significant differences were found but clinical importance is unclear. Because the
treatment effects are similar between APAP and CPAP, the therapy of choice may depend on other factors such as
patient preference, specific reasons for non-compliance and cost.
Background
Obstructive sleep apnea (OSA) is a relatively common
disorder in the US. The Wisconsin Sleep Cohort Study,
a prospective natural history study, reported that about
10% of adults aged 30 to 60 years old had clear evidence
of OSA in 1988, when the study began [1]. A National
Sleep Foundation poll in 2005 suggested that as many
as one in four American adults are at high risk of OSA
and could benefit from an evaluation for OSA [2].
The defining characteristic of OSA is a partial or com-
plete obstruction of the airway while sleeping. The most
common first-line therapy is the use of continuous posi-
tive airway pressure (CPAP) devices during sleep. The
CPAP machine directly relieves the airway obstruction
by increasing luminal pressure, thereby splinting the air-
way open. When used properly and consistently, CPAP
results in improved sleep patterns and quality of life due
to decreased daytime somnolence. However, many
patients refuse the offer of CPAP therapy, do not
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Patients commonly did not fully comply with CPAP use,
either using the device for only part of the night or only
on some nights. This non-compliance has fueled the
development of a number of technological solutions.
The most common variation on delivering positive air-
way pressure is the use of auto-titrating positive airway
pressure (APAP) devices. Fixed CPAP provides continu-
ous fixed pressure during the entire sleep period. In
contrast, APAP varies the pressure delivered depending
on changes in airflow resistance. Such changes in airflow
resistance during sleep are dependent on many factors
like posture and the degree of nasal congestion. Theore-
tically, varying the pressure delivered would promote an
increase in breathing synchrony with the CPAP device
and therefore could improve patient comfort with the
device and thus enhance compliance. A 2009 Cochrane
review comparing APAP with CPAP concluded that
APAP was slightly more efficacious than CPAP in
increasing patient compliance [4]. We undertook the
present review in the context of a larger review of all
primary studies of treatments for OSA. We sought to
update and expand upon the previous review. The aim
of the present review is to evaluate the body of evidence
regarding the comparative efficacy of APAP versus
CPAP on clinical and sleep-related outcomes, quality of
life, compliance and other outcomes.
Methods
We followed standard systematic review methods as
described in the Agency for Healthcare Research and
Quality (AHRQ) Methods Reference Guide for Effective-
ness and Comparative Effectiveness Reviews [5]. A full
technical report describing these methods in detail,
including literature search strategies, and presenting our
findings in full (with evidence tables) is available else-
where [6].
We searched the MEDLINE and Cochrane Central
Trials Registry databases from study inception to Sep-
tember 2010 for English language studies examining
adults (older than 16 years) with OSA. Our search,
available in the full technical report [6], included terms
for OSA, sleep apnea treatments and relevant research
designs. The full literature search was performed for a
range of key questions about OSA diagnosis, treatment
with any intervention and predictors of outcomes. Six
reviewers independently screened the abstracts. We
used a computerized screening program, abstrackr, to
automate the screening of abstracts for the selection of
eligible articles for full-text screening [7]. The abstrackr
software uses an active learning algorithm to screen for
relevant articles. Relevance was established by manually
double-screening 1,000 abstracts to train the program.
Subsequently, abstracts selected by the program were
screened by one researcher. The results of screening
were iteratively fed into the program for further train-
ing. This process continued until the program was left
with only abstracts it rejected. Using abstrackr, we
reduced by 50% the number of abstracts we needed to
manually screen prior to starting the subsequent steps
of the systematic review. Later, all abstracts rejected by
abstrackr were manually screened for confirmation and
were eventually rejected. Full-text articles were
rescreened for eligibility by the same six reviewers.
We included peer reviewed, randomized controlled
trials (RCTs) that compared APAP with fixed CPAP in
≥10 patients per intervention with confirmed diagnoses
of OSA, including a formal sleep study demonstrating
an apnea-hypopnea index (AHI) ≥5e v e n t s / h o u r .W e
included studies of any duration, though CPAP had to
be used by the patients at home. Outcomes of interest
included: objective clinical outcomes (death, cardiovas-
cular events, hypertension, non-insulin dependent dia-
betes, depression); sleep and wakefulness related clinical
outcomes (quality of life, sleepiness measures, neurocog-
nitive tests, accidents, productivity); sleep study mea-
sures (AHI, arousal index, deep sleep, sleep efficiency,
minimum oxygen saturation); comorbidity intermediate
outcomes (hemoglobin A1c, blood pressure); compli-
ance; and adverse events or harms.
Data from each study were extracted by one of six
reviewers and confirmed by another. Extracted data
included information on study and patient characteris-
tics, details concerning the CPAP devices used, out-
comes and study quality. For most outcomes, only data
from the last reported time-point were included. We
assessed the methodological quality of each study on the
basis of predefined criteria in accordance with AHRQ’s
suggested methods for systematic reviews [5]. The pri-
mary data extractor determined the study quality (rated
with the letter grades A, B or C), and at least one other
reviewer confirmed it. Quality A studies adhered most
closely to the commonly held precepts of high quality,
including clear descriptions of the population, setting,
interventions, outcomes and design; no obvious report-
ing omissions or errors; fewer than 20% dropouts; and
no obvious source of bias. Quality B studies had some
deficiencies in these criteria that were, however, unlikely
to engender a major bias. Quality C studies had inade-
quate descriptions of their studies or had substantial
flaws in reporting or design, such that a major bias
could not be excluded.
We performed random effects model meta-analyses of
differences of selected continuous variables between
interventions where there were at least three unique
similar studies [8]. Based on available data and our a
priori assessment of the clinical importance of specific
outcomes, we performed meta-analyses for the AHI, the
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frequency of arousals from sleep), minimum oxygen
saturation (during sleep), the multiple sleep latency test
(measurement of how quickly a subject will fall asleep
during the day), the quality of life measure Functional
Outcomes Sleep Questionnaire and compliance (mea-
sured as time per night using the device). When neces-
sary, standard errors of the net change (difference
between the within-arm changes) were calculated from
CIs, P values or from the standard errors of the within-
arm changes. When necessary, standard errors of the
within-arm changes were estimated from the standard
errors of the baseline and final values, assuming a 50%
correlation between the two. Studies that compared two
different forms of APAP to CPAP were treated as inde-
pendent despite the common CPAP arm. Due to limita-
tions of the reported data and for consistency, in cross-
over studies we treated the difference in final values as
equivalent to the net change, under the assumption that
the baseline values were equal and would thus cancel
out. Heterogeneity among effect sizes was assessed using
the I
2 index, and the chi-square test. An I
2 index ≥50%
was used to indicate medium-to-high heterogeneity [9].
To explore sources of heterogeneity in between-study
findings, all forest plots were drawn with subgroup
meta-analyses of trials stratified by baseline OSA sever-
ity (as determined by the minimum AHI threshold
required in each study for the diagnosis of OSA). Forest
plots sub-divided by study design are presented in the
full technical report [6]. The decision to subgroup stu-
dies by minimum AHI and by study design was made a
priori; however, the minimum AHI categories were
based on thresholds reported in the studies. We per-
formed meta-regressions separately with AHI thresholds
and study design to determine statistically significant
differences among subgroups.
We graded the strength of the body of evidence based
on the AHRQ Methods Reference Guide [5]. We took
into account the overall study quality, the consistency
across studies, the applicability of the studies to the gen-
eral population of patients treated for OSA, the magnitude
and precision of the treatment effects and the relative clin-
ical importance of the different outcomes assessed [6].
The overall strength of evidence was rated as high, moder-
ate, or low - which each indicate the level of confidence
that the evidence reflects the true effect - or insufficient.
Results
Our literature search yielded 15,816 citations, from
which 861 articles were retrieved (Figure 1). We identi-
fied 24 RCTs that compared APAP with fixed CPAP
treatment in patients with OSA (Table 1; [10-33]).
Three RCTs [31-33] identified in prior meta-analyses
[4,34] were added after completion of our full technical
report [6]. Fifteen trials used a cross-over design and
nine a parallel design. Studies generally failed to report
complete data about outcomes. For 17 studies, the var-
iance of the difference in baseline and final values was
not reported and had to be estimated by making an
assumption about the correlation between the values.
Patients who were new to positive airway pressure treat-
ments were enrolled in 21 of 24 studies (three did not
provide this information). There was a broad range of
OSA severity at baseline across studies;p a t i e n t s ’ mean
baseline AHI ranged from 15 to 58 events/hour. In all
studies, most patients were either overweight or obese
(body mass index ranged from 29.9 to 42 kg/m
2). None
of the studies selectively focused on patients with other
comorbidities. Study sample sizes ranged from 10 to 181
patients (total 1017 across studies). Study durations ran-
ged from three weeks to nine months, with the majority
of studies lasting three months or less. Two trials were
rated quality A, 12 were rated quality B and ten rated
quality C. Primary methodological concerns included
small sample sizes without statistical power calculations,
incomplete data reporting, short follow-up durations
and high dropout rates. Based primarily on the eligibility
criteria and baseline characteristics of the trial, the out-
comes are applicable mainly to newly diagnosed (pre-
viously untreated) OSA patients with AHI > 15 events/
hour and body mass index > 30 kg/m
2. Outcome-speci-
fic tables summarizing the trials and their results can be
found Table 2 (compliance), Table 3 (AHI), Table 4
(ESS), Table 5 (arousal index), Table 6 (minimum O2
Citations identified in MEDLINE, Cochrane
Central Trials Registry, and Cochrane Database
of Systematic Reviews search for primary
studies, published through September 2010
(n=15,816)
Primary study articles retreived for full-text review
(n=861)
Abstracts failed to
meet criteria
(n=14,955)
Eligible trials
(n=24)
Articles failed to
meet criteria
(n= 612)
Articles relevant to
other research
questions
(n=226)
Figure 1 Literature selection flow.
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Page 3 of 24Table 1 Randomized controlled trials of APAP versus CPAP: baseline study characteristics
Study
PMID
Study
design
Mean
age
(years)
Male,
%
Mean body
mass index
(kg/m
2)
Baseline
AHI (SD)
Previous
CPAP?
Funding Quality issues
d’Ortho 2000 [32]
11035671
XO 57 88 32 58 (6) No Industry/Non-
industry
combined
-
Damjanovic 2009 [10]
19129293
PL 57 78 31.1 44 (25) No
(new Dx)
nd -
Fietze 2007 [11]
17337881
PL 54 95 30.9 42 (26) No
(new Dx)
Industry Incomplete reporting; patient
selection unclear
Galetke 2008 [12]
17148931
XO 56 80 29.3 33 (19) No
(new Dx)
nd Incomplete reporting; small sample
and no power calculation
Hudgel 2000 [18]
10947032
XO 46 54 42 30 (25) No nd Incomplete reporting; 35% dropout
Hukins 2004 [19]
15683142
XO 50 87 35.2 50 (25) No Industry -
Hussain 2004 [20]
15072173
XO 45 90 35.9 47 (36) No Industry Patient recruitment method unclear;
small sample and no power
calculation
Konermann 1998 [31]
9515848
PL 54 88 32.1 38 (14) nd nd -
Marrone 2004 [21]
15165530
XO 53 95 32.9 68 (12) No nd Small sample and no power
calculation
Massie 2003 [22]
12406840
XO 49 82 32 nd No
(new Dx,
implied)
Industry Incomplete reporting
Meurice 2007 [13]
17638595
PL 55 nd 30.8 55 (10) No
(no Tx)
nd Patient recruitment unclear
Nolan 2007 [14]
17326544
XO 53 90 29.9 15 (8) No
(new Dx)
Non-industry -
Noseda 2004 [23]
15249439
XO 49 96 32.3 nd No nd -
Nussbaumer 2006 [15]
16537862
XO 49 90 31.1 41 (20) nd Industry -
Patruno 2007 [16]
17494789
PL 48 81 36.5 46 (14) No
(new Dx)
Non-industry Incomplete reporting
Planes 2003 [29]
12683473
PL 54 77 32.4 59 (17) No
(new Dx)
Industry
(unclear)
Patient recruitment unclear
Randerath 2001 [26]
11254519
XO 55 87 32.4 35 (26) nd Industry -
Resta 2004 [24]
15679008
PL 33 90 36.7 47 (11) No
(no Tx)
nd Incomplete reporting
Senn 2003 [25]
14525804
XO 53 79 33.3 46 (23) No nd -
Sériès 1997 [27]
9341056
PL 36-65
(range)
nd 36.4 44 (20) No
(no Tx)
Industry Potential selection bias
Teschler 2000 [28]
10885414
XO 52 100 33.8 53 (26) No
(new Dx)
nd Incomplete reporting; small sample
To 2008 [17]
18197915
XO 46 nd 28.7 54 (nd) No
(new Dx)
nd -
Vennelle 2010 [30]
20175411
XO 50 77 34.5 33 (18) No
(new Dx)
nd -
West 2006 [33]
16254055
PL 46.5
a 85 nd nd No Industry -
APAP: auto-titrating CPAP; CPAP: continuous positive airway pressure; nd: no data; new Dx: a new diagnosis of sleep apnea; no Tx: no prior treatment; PL:
parallel; XO: cross-over.
aMedian of the CPAP arm.
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Page 4 of 24Table 2 Compliance (mean hours/night) in randomized controlled trials of APAP versus CPAP
Study
PMID
Baseline
AHI (SD)
[Eligibility]
Baseline
ESS (SD)
Duration
(design)
Interventions Number
analyzed
Final Change
(final)
Net
difference
or
difference
P Dropout
(%)
Study
quality
d’Ortho 2000 [32]
11035671
58 (6)
[≥10]
12.7 (5.3) 2 months
(XO)
APAP 25 4.1 -0.6 -1.5, 0.32
a 0.20 0 B
CPAP 25 4.7
Damjanovic 2009
[10]
19129293
44 (25)
[≥15]
8.8 (5.2) 3 months
(PL)
APAP 46 5.4 0 -0.7, 0.7 nd 8 B
CPAP 46 5.4
9 months
(PL)
APAP 34 5.2 0.1 -0.9, 1.1 nd 22
CPAP 44 5.1
Fietze 2007 [11]
17337881
42 (26)
[≥10]
nd 1.5 months
(PL)
APAP 20 5.0 0.8 nd NS 0 C
CPAP 21 4.2
Galetke 2008 [12]
17148931
33 (19)
[> 10]
10.3 (5.7) 2 months
(XO)
APAP 20 6.37 -0.01 -0.82, 0.8 nd nd C
CPAP 20 6.38
Hudgel 2000 [18]
10947032
30 (25)
[nd]
16.0 (5.0) 3 months
(XO)
APAP 14 6.0 0.5 0.02, 0.98
a < 0.04 35 C
CPAP 19 5.5
Hukins 2004 [19]
15683142
56 (nd) 12.5 (nd) 1 to 2
months
(XO)
APAP 46 5.05 0.19 -0.06, 0.44
a 0.14 16 B
CPAP 46 4.86
Hussain 2004 [20]
15072173
47 (36)
[> 15]
11.1 (6.4) 1 month
(XO)
APAP 10 4.3 0.6 -0.84, 2.04 nd 0 C
CPAP 10 3.7
Konermann 1998
[31]
9515848
38 (14)
[> 20]
nd 3 to 6
months
(PL)
APAP 25 6.5 0.8 0.19, 1.41
a <0 . 0 1 4 B
CPAP 23 5.7
Marrone 2004 [21]
15165530
68 (12)
[30]
16.3 (5.0) 1 month
(XO)
APAP 22 4.9 0.5 -0.26, 1.26 nd 0 C
CPAP 22 4.4
Massie 2003 [22]
12406840
nd
[≥15]
nd 1.5 months
(XO)
APAP 44 5.1 0.58 0.18, 0.99
a 0.005 4 B
CPAP 44 4.52
Meurice 2007 [13]
17638595
55 (10)
[nd]
11.8 (4.9) 3 months
(PL)
APAP
(AutoSet)
15 6.0 -0.1 -0.79, 0.59 nd 15 B
CPAP 14 6.1
6 months
(PL)
APAP
(AutoSet)
15 6.1 -0.4 -1.28, 0.48 nd 15
CPAP 14 6.5
Nolan 2007 [14]
17326544
15 (8)
[≥5]
12.3 (4.0) 2 months
(XO)
APAP 29 4.9 0 nd 0.94 15 B
CPAP 29 4.9
Noseda 2004 [23]
15249439
51 (25) [>
20]
10.7 (2.4) 2 months
(XO)
APAP 24 5.3 -0.2 -0.89, 0.49 nd 11 B
CPAP 24 5.5
Nussbaumer 2006
[15]
16537862
41 (20)
[> 10]
12.7 (3.3) 1 month
(XO)
APAP 30 5.1 0.3 -0.29, 0.89 nd 12 B
CPAP 30 4.8
Patruno 2007 [16]
17494789
46 (14)
[> 20]
15 (2.7) 3 months
(PL)
APAP 15 6.2 0.2 -0.25, 0.65 nd 23 C
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Page 5 of 24saturation), Table 7 (sleep efficiency), Table 8 (rapid eye
movement (REM) sleep), Table 9 (stage 3 or 4 sleep)
and Table 10 (quality of life and functional outcomes).
Objective clinical outcomes
No trial evaluated clinical outcomes, including death;
cardiovascular events such as myocardial infarction,
heart failure or stroke; or diabetes or depression
severity.
Compliance
All 24 included trials reported data on compliance. The
number of hours used per night was derived from
machine-recorded compliance data. No statistically sig-
nificant differences were observed in device usage
(hours used per night) between APAP and CPAP in 20
of the trials, while four reported a significant increase in
the use of APAP compared with CPAP [17,18,22,30].
Twenty-two trials provided sufficient data for meta-
Table 2 Compliance (mean hours/night) in randomized controlled trials of APAP versus CPAP (Continued)
CPAP 16 6.0
Planes 2003 [29]
12683473
59 (17)
[≥30]
15.1 (3.9) 2 months
(PL)
APAP 16 4.5 -0.8 nd NS 14 C
CPAP 14 5.3
Randerath 2001
[26]
11254519
35 (26)
[≥10]
11.1 (5.1) 1.5 months
(XO)
APAP 46 5.26 0 -0.44, 0.44 nd 12 B
CPAP 46 5.26
Resta 2004 [24]
15679008
47 (11)
[> 30]
13.9 (3.2) 1 month
(PL)
APAP 10 5.2 -0.1 -1.12, 0.92 nd 0 C
CPAP 10 5.3
Senn 2003 [25]
14525804
46 (23)
[> 10]
14.2 (3.8) 1 month
(XO)
APAP
(Autoset T)
29 5.5 -0.1 nd NS 7 B
APAP
(AutoAdjust)
29 5.5 -0.1 nd NS
CPAP 29 5.6
Sériès 1997 [27]
9341056
44 (20)
[nd]
15.5 (4.5) 0.75
months
(PL)
APAP
b 12 nd
c -- N S 0 C
CPAP 12 nd
APAP
d 12 nd
c -- N S
CPAP 12 nd
Vennelle 2010
[30]
20175411
33 (18)
[≥15]
14 (3) 6 weeks
(XO)
APAP 181 4.2 0.2 0.003,
0.397
0.047 9.5 A
CPAP 181 4.0
Teschler 2000 [28]
10885414
53 (26)
[> 20]
nd 2 months
(XO)
APAP 10 6.3 0.2 -0.7, 1.1 nd nd C
CPAP 10 6.1
To 2008 [17]
18197915
54 (nd)
[> 30]
13.4 (nd) 1 month
(XO)
APAP 41 4.3 0.5 0.02, 0.98 0.04 5 B
CPAP 41 3.8
2 months
(XO)
APAP 41 4.4 0.7 0.17, 1.23
a 0.01
CPAP 41 3.7
West 2006 [33]
16254055
33
e (nd)
[> 10]
16.5
f (nd) 1 month
(PL)
APAP 29 5.3 0.27 6.1 A
CPAP (auto) 31 4.3
CPAP (algo) 32 4.7
6 months
(PL)
APAP 28 5.5 0.23
CPAP (auto) 31 4.9
CPAP (algo) 27 4.0 9.2
AHI: apnea-hypopnea index (events/hour); algo: fixed pressure CPAP determined by algorithm; APAP: auto-titrating CPAP; auto: fixed pressure CPAP determined
by pressures from 1 week of APAP; CPAP: continuous positive airway pressure; ESS: Epworth Sleepiness Scale; nd: no data; NS: non-significant; PL: parallel design;
XO: cross-over design.
aEstimated from reported P value.
bEstimated effective pressure.
cDirections of changes not reported in the study.
dMeasured effective
pressure.
e> 4% SaO2 dip rate per hour in algorithm-determined CPAP arm, median.
fMedian in algorithm-determined CPAP arm.
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Page 6 of 24Table 3 AHI (events/hour) in randomized controlled trials of APAP versus CPAP
Study
PMID
Baseline AHI
(SD)
[eligibility]
Baseline ESS
(SD)
Duration
(design)
Interventions Number
analyzed
Baseline
(SD)
Change
(final)
Net
difference
or
difference
95% CI
a P Dropout
(%)
Study
quality
d’Ortho 2000 [32]
11035671
58 (6)
[≥10]
12.7 (5.3) 2 months
(XO)
APAP 25 57.8 (5.8) -47.2 0.9 nd NS 0 B
CPAP 25 57.8
(5.8)
-48.1
Damjanovic 2009 [10]
19129293
44 (25)
[≥15]
8.8 (5.2) 3 months
(PL)
APAP 46 41.8 (23.7) -37.0 1.8 -7.14 to
10.74
nd 8 B
CPAP 46 45.5 (24.4) -38.8
9 months
(PL)
APAP 34 41.8 (23.7) -38.2 1.9 -6.86 to
10.66
nd 22
CPAP 44 45.5 (24.4) -40.1
Fietze 2007 [11]
17337881
42 (26)
[≥10]
nd 1.5 months
(PL)
APAP 20 43.3 (30.2) -38.9 0.5 -1.19 to 2.19 nd 0 C
CPAP 21 40.4 (26.1) -36.5
Galetke 2008 [12]
17148931
33 (19)
[> 10]
10.3 (5.7) 2 months
(XO)
APAP 20 32.9 (19.1) -27.3 1.0 -0.45 to 2.45 nd nd C
CPAP 20 32.9 (19.1) -28.3
Hussain 2004 [20]
15072173
47 (36)
[> 15]
11.1 (6.4) 1 month
(XO)
APAP 10 47.2 (35.6) -34.1 3.5 -1.02 to 8.02 nd 0 C
CPAP 10 47.2 (35.6) -37.6
Konermann 1998 [31]
9515848
38 (14)
[> 20]
nd 3 to 6 months
(PL)
APAP 25 35.5
(9.6)
-33.1 1.6 nd NS 4 B
CPAP 23 38.3
(13.9)
-34.7
Massie 2003 [22]
12406840
nd
[≥15]
nd 1.5 months
(XO)
APAP 44 nd nd -1.1 -2.89 to 0.69 nd 4 B
CPAP 44 nd nd
Meurice 2007 [13]
17638595
55 (10)
[nd]
11.8 (4.9) 6 months
(PL)
APAP (AutoSet) 15 53.4 (15.1) -51.1 2.6 -8.88 to
14.08
nd 15 B
CPAP 14 56.1
(21.4)
-53.7
Nolan 2007 [14]
17326544
15 (8)
[≥5)
12.3 (4.0) 2 months
(XO)
APAP 29 14.7 (8) -12.0 -0.8 -1.89 to
0.29
b
0.15 15 B
CPAP 29 14.7 (8) -11.2
Nussbaumer 2006 [15]
16537862
41 (20)
[> 10]
12.7 (3.3) 1 month
(XO)
APAP 30 41.1 (19.7) -36.5 -0.8 -1.7 to 3.3
c nd 12 B
CPAP 30 41.2 (19.7) -35.7
Patruno 2007 [16]
17494789
46 (14)
[> 20]
15 (2.7) 3 months
(PL)
APAP 15 47.3 (14.7) -41.3 2.7 -7.01 to
12.41
nd 23 C
CPAP 16 46.0
(14.6)
-44.0
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Planes 2003 [29]
12683473
59 (17)
[≥30]
15.1 (3.9) 2 months
(PL)
APAP 16 57.5 (16.5) -49.9 0.7 -10.06 to
11.46
nd 14 C
CPAP 14 61.0
(17.4)
-50.6
Randerath 2001 [26]
11254519
35 (26)
[≥10]
11.1 (5.1) 1.5 months
(XO)
APAP 52 35.1 (26) -30.1 0.7 -0.88 to 2.28 nd 12 B
CPAP 52 35.1 (26) -30.8
Resta 2004 [24]
15679008
47 (11)
[> 30]
13.9 (3.2) 1 month
(PL)
APAP 10 48.0
(14.3)
-39.7 -2.8 -12.96 to
7.36
nd 0 C
CPAP 10 45.3 (10.7) -36.9
Senn 2003 [25]
Switzerland
14525804
46 (23)
[> 10]
14.2 (3.8) 1 month
(XO)
APAP (Autoset
T)
29 45.8 (22.6) -39.8 0.7 -1.26 to 2.66 nd 7 B
APAP
(AutoAdjust)
29 45.8 (22.6) -38.1 2.4 -0.34 to 5.14 nd
CPAP 29 45.8
(22.6)
-40.5
Sériès 1997 [27]
9341056
44 (20)
[nd]
15.5 (4.5) 0.75 months
(PL)
APAP
d 12 61.5 (27.9) nd
e -- N S 0 C
CPAP 12 50.1 (14.5) nd
APAP
f 12 46.8 (22.3) nd
e -- N S
CPAP 12 50.1 (14.5) nd
AHI: apnea-hypopnea index (events/hour); APAP: auto-titrating CPAP; CPAP: continuous positive airway pressure; ESS: Epworth Sleepiness Scale; nd: no data; NS: non-significant; PL: parallel design; XO: cross-over
design.
aEstimated from reported data.
bEstimated from reported P value.
cActual reported data.
dEstimated effective pressure.
eDirections of changes not reported in the study.
fMeasured effective pressure.
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4Table 4 ESS in randomized controlled trials of APAP versus CPAP
Study
PMID
Baseline AHI
(SD)
[eligibility]
Baseline ESS
(SD)
Duration
(design)
Interventions Number
analyzed
Baseline
(SD)
Change
(final)
Net
difference
or
difference
95% CI
a P Dropout
(%)
Study
quality
d’Ortho 2000 [32]
11035671
58 (6)
[≥10]
12.7 (5.3) 2 months
(XO)
APAP 25 12.7 (5.3) -3.4 0.1 nd NS 0 B
CPAP 25 12.7
(5.3)
-3.5
Damjanovic 2009 [10]
19129293
44 (25)
[≥15]
8.8 (5.2) 3 months
(PL)
APAP 46 8.5 (5.4) -2.6 -0.3 -2.32 to
1.72
nd 8 B
CPAP 46 9.3 (4.8) -2.3
9 months
(PL)
APAP 34 8.5 (5.4) -2.6 0.1 -1.92 to
2.12
nd 22
CPAP 44 9.3 (4.8) -2.7
Fietze 2007 [11]
17337881
42 (26)
[≥10]
nd 1.5 months
(PL)
APAP 20 nd nd nd nd NS 0 C
CPAP 21 nd nd
Galetke 2008 [12]
17148931
33 (19)
[> 10]
10.3 (5.7) 2 months
(XO)
APAP 20 10.3 (5.7) -5.4 -1.7 -3.76 to
0.36
nd 0 C
CPAP 20 10.3 (5.7) -3.7
Hudgel 2000 [18]
10947032
30 (25)
[nd]
16.0 (5.0) 3 months
(XO)
APAP 39 16.0 (5.0) -7.0 1 -0.96 to
2.96
nd 35 C
CPAP 39 16.0 (5.0) -8.0
Hussain 2004 [20]
15072173
47 (36)
[> 15]
11.1 (6.4) 1 months
(XO)
APAP 10 11.1 (6.4) -3.1 1.4 -2.2 to 5.0 nd 0 C
CPAP 10 11.1 (6.4) -4.5
Hukins 2004 [19]
15683142
56 (nd)
[≥5]
12.5 (nd) 1 to 2 months
(XO)
APAP 46 12.5 (nd) -4.5 -0.2 nd NS 16 B
CPAP 46 12.5 (nd) -4.3
Marrone 2004 [21]
15165530
68 (12)
[30]
16.3 (5.0) 1 month
(XO)
APAP 22 16.3 (5.0) -12.4 -1 -2.4 to 0.4 nd 0 C
CPAP 22 16.3 (5.0) -11.4
Massie 2003 [22]
12406840
nd
[≥15]
nd 1.5 months
(XO)
APAP 44 nd nd -1 -2.06 to
0.06
b
0.065 4 B
CPAP 44 nd nd
Meurice 2007 [13]
17638595
55 (10)
[nd]
11.8 (4.9) 3 months
(PL)
APAP (AutoSet) 15 12.9 (4.3) -9.1 -3.3 -6.68 to
0.08
NS 15 B
CPAP 14 10.6 (5.2) -5.8
6 months
(PL)
APAP (AutoSet) 15 12.9 (4.3) -7.7 -3.0 -6.44 to
0.44
NS 15
CPAP 14 10.6 (5.2) -4.7
Nolan 2007 [14]
17326544
15 (8)
[≥5)
12.3 (4.0) 2 months
(XO)
APAP 29 12.3 (4.0) -3.7 0.9 -0.99 to
2.79
b
0.35 15 B
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4Table 4 ESS in randomized controlled trials of APAP versus CPAP (Continued)
CPAP 29 12.3 (4.0) -4.6
Noseda 2004 [23]
15249439
nd [> 20] 10.7 (2.4) 2 months
(XO)
APAP 24 10.7 (2.4) nd -1 -1.76 to
-0.24
b
<
0.01
11 B
CPAP 24 10.7 (2.4) nd
Nussbaumer 2006 [15]
16537862
41 (20)
[> 10]
12.7 (3.29) 1 month
(XO)
APAP 30 12.7
(0.6)
-6.6 0 -1.6 to 1.1 nd 12 B
CPAP 30 12.7
(0.6)
-6.6
Patruno 2007 [16]
17494789
46 (14)
[> 20]
15 (2.7) 3 months
(PL)
APAP 15 15.8 (3.5) nd nd nd NS 23 C
CPAP 16 14.1 (1.7) nd
Planes 2003 [29]
12683473
59 (17)
[≥30]
15.1 (3.9) 2 months
(PL)
APAP 16 15.5 (4.7) -8.0 -0.9 -3.72 to
1.92
nd 14
CPAP 14 14.7 (3.9) -7.1
Randerath 2001 [26]
11254519
35 (26)
[≥10]
11.1 (5.1) 1.5 months
(XO)
APAP 52 11.1 (5.1) -3.3 -1 -2.26 to
0.26
nd 12 B
CPAP 52 11.1 (5.1) -2.3
Resta 2004 [24]
15679008
47 (11)
[> 30]
13.9 (3.2) 1 month
(PL)
APAP 10 15.7 (5.1) -10.5 -2.6 -5.84 to
0.64
nd 0 C
CPAP 10 12.0
(3.2)
-7.9
Senn 2003 [25]
Switzerland
14525804
46 (23)
[> 10]
14.2 (3.77) 1 month
(XO)
APAP (Autoset
T)
29 14.2 (3.77) -5.2 0.8 -0.49 to
2.09
nd 7 B
APAP
(AutoAdjust)
29 14.2 (3.77) -6.2 -0.2 -1.68 to
1.28
nd
CPAP 29 14.2 (3.77) -6.0
Sériès 1997 [27]
9341056
44 (20)
[nd]
15.5 (4.5) 0.75 months
(PL)
APAP
c 12 17.0
(4.1)
-9.1 -0.8 -4.28 to
2.69
nd 0 C
CPAP 12 16.1 (4.5) -8.3
APAP
d 12 13.5
(4.7)
-6.5 1.8 -1.78 to
5.38
nd
CPAP 12 16.1
(4.5)
-8.3
To 2008 [17]
18197915
54 (nd)
[> 30]
13.4 (nd) 1 month
(XO)
APAP 41 13.4 (5.76) -4.9 0.3 -1.46 to
2.06
nd 5 B
CPAP 41 13.4 (5.76) -5.2
2 months
(XO)
APAP 41 13.4 (5.76) -4.9 0 -1.76 to
1.76
nd
CPAP 41 13.4 (5.76) -4.9
Vennelle 2010 [30]
20175411
33 (18) [≥15] 14 (3) 6 weeks (XO) APAP 181 14 (3) -4.5 -0.5 -0.95 to
-0.05
0.031 9.5 A
CPAP 181 14 (3) -4
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4Table 4 ESS in randomized controlled trials of APAP versus CPAP (Continued)
West 2006 [33] 33
e (nd)
[> 10]
16.5
f(nd) 1 month
(PL)
APAP 29 16
(median)
7 (final) 0.9 6.1 A
CPAP (auto) 31 17
(median)
7 (final)
CPAP (algo) 32 16.5
(median)
6 (final)
6 months
(PL)
APAP 28 16
(median)
6 (final) 0.8 9.2
CPAP (auto) 31 17
(median)
5 (final)
CPAP (algo) 27 16.5
(median)
5 (final)
AHI: apnea-hypopnea index (events/hour); algo: fixed pressure CPAP determined by algorithm; APAP: auto-titrating CPAP; auto: fixed pressure CPAP determined by pressures from 1 week of APAP; CPAP: continuous
positive airway pressure; ESS: Epworth Sleepiness Scale; nd: no data; NS: non-significant; PL: parallel design; XO: cross-over design.
aEstimated from reported data.
bEstimated from reported P value.
cEstimated
effective pressure.
dMeasured effective pressure.
e> 4% SaO2 dip rate per hour in algorithm-determined CPAP arm.
fMedian in algorithm-determined CPAP arm.
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4Table 5 Arousal index (events/hour) in randomized controlled trials of APAP versus CPAP
Study
PMID
Baseline
AHI (SD)
[eligibility]
Baseline
ESS (SD)
Duration
(design)
Interventions Number
analyzed
Baseline
(SD)
Change
(final)
Net
difference
or
difference
95%
CI
a
P Dropout
(%)
Study
quality
d’Ortho
2000 [32]
11035671
58 (6)
[≥10]
12.7 (5.3) 2 months
(XO)
APAP 25 45.6
(25.8)
-30.1 1.8 nd NS 0 B
CPAP 25 45.6
(25.8)
-31.9
Damjanovic
2009 [10]
19129293
44 (25)
[≥15]
8.8 (5.18) 3 months
(PL)
APAP 46 30.6
(22.4)
-18.3 -0.2 -7.92 to
7.52
nd 8 B
CPAP 46 34.5
(21.0)
-18.1
9 months
(PL)
APAP 34 30.6
(22.4)
-17.7 3.6 -4.09 to
11.29
nd 22
CPAP 44 34.5
(21.0)
-21.3
Galetke
2008 [12]
17148931
33 (19)
[> 10]
10.3 (5.7) 2 months
(XO)
APAP 20 17.6 (9.2) -4.0 1.0 -2.52 to
4.52
nd nd C
CPAP 20 17.6 (9.2) -5.0
Hussain
2004 [20]
15072173
47 (36)
[> 15]
11.1 (6.4) 1 month
(XO)
APAP 10 17.3
(17.7)
-11.4 1.0 -2.5 to
4.5
nd 0 C
CPAP 10 17.3
(17.7)
-12.4
Konermann
1998 [31]
9515848
38 (14)
[> 20}
nd 3 to 6
months
(PL)
APAP 25 16.9
(10.5)
-9.5 -3.3 -6.6 to
0
b
<
0.05
4B
CPAP 23 13.3
(13.3)
-6.2
Nolan 2007
[14]
17326544
15 (8)
[≥5)
12.3 (4) 2 months
(XO)
APAP 29 16.0
(14.0)
-14.0 -3.0 -5.7 to
-0.29
b
0.03 15 B
CPAP 29 16.0
(14.0)
-11.0
Planes 2003
[29]
12683473
59 (17)
[≥30]
15.1 (3.9) 2 months
(PL)
APAP 16 44.4
(19.1)
3.3 -7.14 to
12.74
nd 14 C
CPAP 14 48.5
(14.2)
Randerath
2001 [26]
11254519
35 (26)
[≥10]
11.1 (5.1) 1.5
months
(XO)
APAP 52 34 (21.7) -23.1 -1.7 -3.7 to
0.3
nd 12 B
CPAP 52 34 (21.7) -21.4
Resta 2004
[24]
15679008
47 (11)
[> 30]
13.9 (3.2) 1 month
(PL)
APAP 10 43.1
(11.9)
-35.7 0.1 -8.29 to
8.49
nd 0 C
CPAP 10 43.1 (9.1) -35.8
Sériès 1997
[27]
9341056
44 (20)
[nd]
15.5 (4.5) 0.75
months
(PL)
APAP
c 12 nd nd - - NS 0 C
CPAP 12 nd nd
APAP
d 12 nd nd - - NS
CPAP 12 nd nd
AHI: apnea-hypopnea index (events/hour); APAP: auto-titrating CPAP; CPAP: continuous positive airway pressure; ESS: Epworth Sleepiness Scale; nd: no data; NS:
non-significant; PL: parallel design; XO: cross-over design.
aEstimated from reported data.
bEstimated from reported P value.
cEstimated effective pressure.
dMeasured effective pressure.
Ip et al. Systematic Reviews 2012, 1:20
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Page 12 of 24analysis, which showed a statistically significant differ-
ence of 11 minutes per night favoring APAP (difference
= 0.18 hours; 95% CI, 0.05 to 0.31 minutes; P = 0.006),
without statistical heterogeneity (Figure 2).
To test the ap r i o r ihypothesis that the relative effect
on compliance may differ based on baseline severity, we
performed subgroup meta-analyses stratified by mini-
mum AHI threshold. By meta-regression, the subgroups
had no significantly different effects from each other.
Results were also similar in parallel and cross-over
design studies.
Apnea-hypopnea index
Sixteen trials provided sufficient data for analysis of resi-
dual AHI while using treatment (Figure 3) [10-16,
20,22,24-26,28,29,31,32]. None of the studies reported a
statistically significant difference in AHI (events/hour)
between APAP and CPAP. The mean net difference in
i n d i v i d u a ls t u d i e sr a n g e df r o m- 2 . 8t o3 . 5e v e n t s / h o u r ,
where negative values favor APAP. Meta-analysis across
these studies indicated a non-significant difference
between APAP and CPAP of 0.25 events/hour (95% CI,
-0.16 to 0.66 events/hour; P =0 . 2 3 ) .N os t a t i s t i c a l l y
Table 6 Minimum O2 saturation (%) in randomized controlled trials of APAP versus CPAP
Study
PMID
Baseline
AHI (SD)
[eligibility]
Baseline
ESS (SD)
Duration
(design)
Interventions Number
analyzed
Baseline
(SD)
Change
(final)
Net
difference
or
difference
95%
CI
a
P Dropout
(%)
Study
quality
d’Ortho 2000
[32]
11035671
58 (6)
[≥10]
12.7 (5.3) 2 months
(XO)
APAP 25 66.5
(13.6)
85.2 -1.4 nd nd 0 B
CPAP 25 66.5
(13.6)
86.6
Galetke 2008
[12]
17148931
33 (19)
[> 10]
10.3 (5.7) 2 months
(XO)
APAP 20 77.8 (8.4) 8.7 -1.8 -3.8
to 0.2
nd nd C
CPAP 20 77.8 (8.4) 10.5
Hussain 2004
[20]
15072173
47 (36)
[> 15]
11.1 (6.4) 1 month
(XO)
APAP 10 67.8
(12.5)
14 -3.9 -7.3
to
-0.5
nd 0 C
CPAP 10 67.8
(12.5)
17.9
Konermann 1998
[31]
9515848
38 (14)
[> 20}
nd 3 to 6
months
(PL)
APAP 25 76.5
(12.4)
90.3 1.1 nd NS 4 B
CPAP 23 74.5
(10.7)
87.2
Meurice 2007
[13]
17638595
55 (10)
[nd]
11.8 (4.9) 6 months
(PL)
APAP
(AutoSet)
15 82.1
(12.8)
0.2 -2.9 -7.1
to 7.5
nd 15 B
CPAP 14 82.3
(9.9)
0.5
Nolan 2007 [14]
17326544
15 (8)
[≥5)
12.3 (4) 2 months
(XO)
APAP 29 79 (11.5) 8.5 4.8 -7.4
to
17.0
b
0.44 15 B
CPAP 29 79 (11.5) 3.7
Patruno 2007
[16] 17494789
46 (14)
[> 20]
15 (2.7) 3 months
(PL)
APAP 15 71.7
(10.6)
16.4 -4.4 -11.8
to 3.0
nd 23 C
CPAP 16 70.0
(11.7)
20.8
Randerath 2001
[26]
11254519
35 (26)
[≥10]
11.1 (5.1) 1.5
months
(XO)
APAP 52 81 (8.0) 7.0 -1.0 -2.1
to 0.1
nd 12 B
CPAP 52 81 (8.0) 8.0
Resta 2004 [24]
15679008
47 (11)
[> 30]
13.9 (3.2) 1 month
(PL)
APAP 10 72.4
(10.5)
15.9 0.9 -7.4
to 9.2
nd 0 C
CPAP 10 74.1
(10.8)
15.0
AHI: apnea-hypopnea index (events/hour); APAP: auto-titrating CPAP; CPAP: continuous positive airway pressure; ESS: Epworth Sleepiness Scale; nd: no data; NS:
non-significant; PL: parallel design; XO: cross-over design.
aEstimated from reported data.
bEstimated from reported P value.
Ip et al. Systematic Reviews 2012, 1:20
http://www.systematicreviewsjournal.com/content/1/1/20
Page 13 of 24significant heterogeneity was observed across studies,
despite a broad range in the severity of OSA at baseline.
Meta-regression stratified by different minimum AHI
thresholds or by study design revealed no apparent dif-
ferences across subgroups in the relative effects of
APAP and CPAP.
Epworth Sleepiness Scale
Twenty-two trials reported ESS after treatment (Figure
4) [10-27,29,30,32,33]. No statistically significant differ-
ences in ESS were observed between APAP and CPAP
in 20 trials, while two studies reported a significant
decrease in ESS favoring APAP [23,30]. The mean net
difference in ESS across all studies ranged from -3.3 to
2.0, where negative values favor less sleepiness with
APAP. Eighteen trials provided sufficient data for meta-
analysis, which yielded a statistically significant differ-
ence between APAP and CPAP of -0.48 (95% CI, -0.81
to -0.15; P = 0.005), favoring APAP. Despite the broad
range of severity of OSA across studies, there was no
statistically significant heterogeneity within the overall
meta-analysis. Meta-regression stratified by minimum
AHI threshold or by study design revealed no apparent
differences across subgroups in relative effects of APAP
and CPAP.
Other sleep study measures
Meta-analysis of nine trials showed a non-significant dif-
ference in arousal index of -0.85 events/hour (95% CI, -2.2
to 0.5 events/hour; P = 0.23), favoring APAP (Figure 5)
[10,12,14,20,24,26,29,31,32]. Meta-analysis of nine trials
showed a statistically significant difference in minimum
oxygen saturation of -1.3% (95% CI, -2.2 to -0.4%; P =
0.003), favoring CPAP (Figure 6) [12-14,16,20,24,26,31,32].
Neither meta-analysis had statistically significant heteroge-
neity. Meta-regression revealed no differences across AHI
or study design subgroups.
The three trials reporting on sleep efficiency (percen-
tage of time asleep while in bed) after a period of treat-
ment did not find a statistically significant difference
between APAP and CPAP for improvement in the per-
centage of time spent asleep [14,24,31]. Nine trials
reporting on percentage of time spent in REM sleep did
not find statistically significant differences between
groups [13,14,20,24,26,27,29,31,32]. Seven of eight trials
found no statistically significant difference in slow wave
sleep (stages 3 or 4) [13,14,20,24,26,27,31,32]. The one
outlier reported a statistically significant net mean
increase of 7.8% (95% CI, 1.8 to 13.7%; P <0 . 0 1 ) ;
patients using APAP spent more time in slow wave
sleep [31]. No study reported effect on the multiple
sleep latency test.
Quality of life
Nine trials evaluated quality of life measures
[11,13,15,17,19,22,25,30,33]. One trial that included the
SF-36
® (Short Form Health Survey) found a significant
difference in the mental health (net difference of 5
points; 95% CI, 0.2 to 9.8 points; P < 0.05) and vitality
(net difference of 7 points; 95% CI, 0.6 to 13.4 points; P
< 0.05) components, favoring those who used APAP
[22]. No other significant differences in quality of life
measures between APAP and CPAP were reported in
this or the other eight trials. One trial reported on the
Sleep Apnea Quality of Life Index and found no differ-
ence between groups [33]. No study reported any effect
on the Functional Outcomes Sleep Questionnaire. Due
to the heterogeneity of specific quality of life outcome
Table 7 Sleep efficiency (%) in randomized controlled trials of APAP versus CPAP
Study
PMID
Baseline
AHI (SD)
[eligibility]
Baseline
ESS (SD)
Duration
(design)
Interventions Number
analyzed
Baseline
(SD)
Change
(final)
Net
difference
or
difference
95%
CI
P Dropout
(%)
Study
quality
Konermann
1998 [31]
9515848
38 (14)
[> 20}
nd 3 to 6
months
(PL)
APAP 25 94.5 (5.4) 2 6 nd NS 4 B
CPAP 23 89.2
(13.7)
-4
Nolan 2007
[14]
17326544
15 (8)
[≥5)
12.3 (4) 2 months
(PL)
APAP 29 79 (9) 4 -1 -4.3
to
2.3
a
0.39 15 B
CPAP 29 79 (9) 5
Resta 2004
[24]
15679008
47 (11)
[> 30]
13.9 (3.2) 1 month
(PL)
APAP 10 86.9
(8)
-0.5 -2.5 nd nd 0 C
CPAP 10 84.2
(4.9)
2
AHI: apnea-hypopnea index (events/hour); APAP: auto-titrating CPAP; CPAP: continuous positive airway pressure; ESS: Epworth Sleepiness Scale; nd: no data; NS:
non-significant; PL = parallel design.
aEstimated from reported data.
Ip et al. Systematic Reviews 2012, 1:20
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Page 14 of 24reported (13 among these studies, including the compo-
nents of SF-36), in Table 10 we summarized only
whether any measure statistically favored APAP or
CPAP and if so, what the net difference was.
Blood pressure
Three trials reported changes in blood pressure
[14,16,33]. Two studies did not find significant differ-
ences in blood pressure changes between the APAP and
CPAP groups [14,33]. In the third study [16], based on
reported data, we estimated a non-significant greater
reduction in systolic blood pressure (net difference = 6
mmHg; 95% CI, -1 to 13 mmHg; P = 0.09) and a signifi-
cant greater reduction in diastolic blood pressure (net
difference = 8 mmHg; 95% CI, 4 to 11 mmHg; P <
0.001) with CPAP compared to APAP.
Adverse effects
No trials reported any unexpected adverse effects with
positive airway treatments. Seven trials reported
Table 8 Rapid eye movement sleep (%) in randomized controlled trials of APAP versus CPAP
Study
PMID
Baseline
AHI (SD)
[eligibility]
Baseline
ESS (SD)
Duration
(design)
Interventions Number
analyzed
Baseline
(SD)
Change
(final)
Net
difference
or
difference
95%
CI
a
P Dropout
(%)
Study
quality
d’Ortho 2000
[32]
11035671
58 (6)
[≥10]
12.7 (5.3) 2 months
(XO)
APAP 25 16
(5)
5- 1 n d n d 0 B
CPAP 25 16
(5)
6
Hussain 2004
[20]
15072173
47 (36)
[> 15]
11.1 (6.4) 1 month
(XO)
APAP 10 15 (7.0) 4.0 -1 -4.72
to
2.72
nd 0 C
CPAP 10 17.6 (5.1) 2.0
Konermann
1998 [31]
9515848
38 (14)
[> 20]
nd 3 to 6
months
(PL)
APAP 25 8.2
(8.1)
11.9 7.1 nd NS 4 B
CPAP 23 5.4
(6.0)
4.8
Meurice 2007
[13]
17638595
55 (10)
[nd]
11.8 (4.9) 6 months
(PL)
APAP
(AutoSet)
15 18.9 (6.6) -2.4 -2.9 -7.49
to
1.69
nd 15 B
CPAP 14 19.1
(5.9)
0.5
Nolan 2007 [14]
17326544
15 (8)
[≥5)
12.3 (4) 2 months
(XO)
APAP 29 17.6 (5.1) -0.5 -2.5 -5.11
to
0.11
b
0.06 15 B
CPAP 29 17.6 (5.1) 2.0
Planes 2003
[29]
12683473
59 (17)
[≥30]
15.1 (3.9) 2 months
(PL)
APAP 16 12.4
(7.0)
4.2 0.5 -5.44
to
6.44
nd 14 C
CPAP 14 13.7 (9.3) 3.7
Randerath 2001
[26]
11254519
35 (26)
[≥10]
11.1 (5.1) 1.5
months
(XO)
APAP 52 11 (8) 6.0 1 -0.63
to
2.63
nd 12 B
CPAP 52 11 (8) 5.0
Resta 2004 [24]
15679008
47 (11)
[> 30]
13.9 (3.2) 1 month
(PL)
APAP 10 15.0
(8.1)
6.7 -2 -10.31
to
6.31
nd 0 C
CPAP 10 15.9 (4.2) 8.7
Sériès 1997 [27]
9341056
44 (20)
[nd]
15.5 (4.5) 0.75
months
(PL)
APAP
c 12 nd nd
d -- N S 0 C
CPAP 12 nd nd
APAP
e 12 nd nd
d -- N S
CPAP 12 nd nd
AHI: apnea-hypopnea index (events/hour); APAP: auto-titrating CPAP; CPAP: continuous positive airway pressure; ESS: Epworth Sleepiness Scale; nd: no data; NS:
non-significant; PL: parallel design; XO: cross-over design.
aEstimated from reported data.
bEstimated from reported P value.
cEstimated effective pressure.
dDirections of changes not reported in the study.
eMeasured effective pressure.
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Page 15 of 24quantitative comparisons of treatment-related side
effects between groups [12,14,15,17,19,25,26]. The side
effects were dry mouth, air leakage, skin or nasal-oral
irritation. No differences in side effects were reported in
five trials [12,14,15,25,26]. Two trials reported that the
use of APAP was associated with significantly fewer
treatment-related side effects [17,19].
Discussion
Despite the lack of evidence on objective clinical out-
comes, given the largely similar magnitude of effects
between APAP and CPAP on sleep measures and
wakefulness assessment and the relatively small increase
(even though statistically significant) in compliance of
about 11 minutes with APAP, we concluded that the
overall strength of evidence is moderate that APAP and
CPAP result in largely similar treatment effects for
patients with OSA (Table 11).
The aim of this study was to systematically compare
the treatment effects of APAP versus fixed CPAP.
Twenty-four trials that included over 1,000 patients pro-
vided evidence that APAP reduces sleepiness as mea-
sured by ESS by approximately 0.5 points more than
fixed CPAP. For compliance, there was a statistically
Table 9 Stage 3 or 4 sleep (%) in randomized controlled trials of APAP versus CPAP
Study
PMID
Baseline
AHI (SD)
[eligibility]
Baseline
ESS (SD)
Duration
(design)
Interventions Number
analyzed
Baseline
(SD)
Change
(final)
Net
difference
or
difference
95%
CI
a
P Dropout
(%)
Study
quality
d’Ortho
2000 [32]
11035671
58 (6)
[≥10]
12.7 (5.3) 2 months
(XO)
APAP 25 44 min
(36)
43 -9 min nd NS 0 B
CPAP 25 44 min
(36)
52
Hussain
2004 [20]
15072173
47 (36)
[> 15]
11.1 (6.4) 1 month
(XO)
APAP 10 14 (25) -4.0 -8 -18.32
to 2.32
nd 0 C
CPAP 10 14 (25) 4.0
Konermann
1998 [31]
9515848
38 (14)
[> 20]
nd 3 to 6
months
(PL)
APAP 25 13.2
(12.2)
14 7.8 1.8 to
13.7
b
<
0.01
4B
CPAP 23 11.4
(10.4)
6.2
Meurice
2007 [13]
17638595
55 (10)
[nd]
11.8 (4.9) 6 months
(PL)
APAP
(AutoSet)
15 25.5
(14.7)
-4.4 -5.2 -13.51
to 3.11
nd 15 B
CPAP 14 17.1
(7)
0.8
Nolan 2007
[14]
17326544
15 (8)
[≥5)
12.3 (4) 2 months
(XO)
APAP 29 13.7 (7.8) 1.3 0.3 -3.29 to
3.89
b
0.87 15 B
CPAP 29 13.7 (7.8) 1.0
Randerath
2001 [26]
11254519
35 (26)
[≥10]
11.1 (5.1) 1.5
months
(XO)
APAP 52 14 (11) 0 -1 -3.45 to
1.45
NS 12 B
CPAP 52 14 (11) 1.0
Resta 2004
[24]
15679008
47 (11)
[> 30]
13.9 (3.2) 1 month
(PL)
APAP 10 19.8
(10.9)
14 7.3 -2.35 to
16.95
nd 0 C
CPAP 10 22.8
(12.5)
6.7
Sériès 1997
[27]
9341056
44 (20)
[nd]
15.5 (4.5) 0.75
months
(PL)
APAP
c 12 nd nd
d -- N S 0 C
CPAP 12 nd nd
APAP
e 12 nd nd
d -- N S
CPAP 12 nd nd
AHI: apnea-hypopnea index (events/hour); APAP: auto-titrating CPAP; CPAP; continuous positive airway pressure; ESS: Epworth Sleepiness Scale; nd: no data; NS:
non-significant; PL: parallel design; XO: cross-over design.
aEstimated from reported data.
bEstimated from reported P value.
cEstimated effective pressure.
dDirections of changes not reported in the study.
eMeasured effective pressure.
Ip et al. Systematic Reviews 2012, 1:20
http://www.systematicreviewsjournal.com/content/1/1/20
Page 16 of 24Table 10 Quality of life and functional outcomes in randomized controlled trials of APAP versus CPAP
Study
PMID
Baseline AHI
(SD)
[eligibility]
Baseline ESS
(SD)
Interventions Number
analyzed
Duration
(design)
Outcome Favors If significant difference Dropout
(%)
Study
quality
Net
difference
95% CI Test range P
“Worst”“ Best”
Fietze 2007 [11]
17337881
42 (26)
[≥10]
nd APAP 20 1.5 months
(XO)
SF-36
all
00 C
CPAP 21
Hukins 2004 [19]
15683142
56 (nd)
[≥5]
12.5 (nd) APAP 46 2 months
(XO)
SF-36-M 0 16 B
CPAP 46
SF-36-P 0
Massie 2003 [22]
12406840
nd
[≥15]
nd APAP 44 1.5 months
(XO)
SF-36 - MH APAP 5 0.16 to
9.8
a
0 100 <
0.05
4B
CPAP 44 SF-36 - vitality APAP 7 0.6 to
13.4
a
0 100 <
0.05
SF-36 -
remainder
0
Meurice 2007 [13]
17638595
55 (10)
[nd]
11.8 (4.9) APAP
(AutoSet)
15 3 months
(PL)
SF-36-M 0 15 B
CPAP 14 SF-36-P 0
6 months
(PL)
SF-36-M 0 15
SF-36-P 0
Nussbaumer 2006
[15]
16537862
41 (20)
[> 10]
12.7 (3.3) APAP 30 1 month
(XO)
SF-36
all
01 2 B
CPAP 30
Senn 2003 [25]
14525804
46 (23)
[> 10]
14.2 (3.8) APAP
(Autoset T)
29 1 month
(XO)
SF-36
all
07 B
APAP
(AutoAdjust)
29 Vigilance
(OSLER)
0
CPAP 29
To 2008 [17]
18197915
54.3 (nd)
[> 30]
13.4 (nd) APAP 41 1 month
(XO)
SAQLI 0 5 B
CPAP 41 2 months
(XO)
SAQLI 0
Vennelle 2010 [30]
20175411
33 (18) [≥15] 14 (3) APAP 181 6 weeks (XO) SF-36-M 0 9.5 A
CPAP 181 SF-36-P 0
Vigilance
(OSLER)
0
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4Table 10 Quality of life and functional outcomes in randomized controlled trials of APAP versus CPAP (Continued)
Vigilance
(Psychomotor)
0
West 2006 [33]
16254055
33
b (nd)
[> 10]
16.5
c (nd) APAP 28 6 months (PL) SF-36-P 0 9.2
CPAP (auto) 31 SF-36-M 0
CPAP (algo) 27 SF-36-energy,
vitality
0
Vigilance
(OSLER)
0
AHI: apnea-hypopnea index (events/hour); algo: fixed pressure CPAP determined by algorithm; APAP: auto-titrating CPAP; auto: fixed pressure CPAP determined by pressures from 1 week of APAP; CPAP: continuous
positive airway pressure; ESS: Epworth Sleepiness Scale; nd: no data; NS: non-significant; PL: parallel design; OSLER: The Oxford Sleep Resistance Test; SAQLI: Sleep Apnea Quality of Life Index; XO: cross-over design.
SF-36 M: Short Form Health Survey Mental Health summary measure. SF_36 P: Short Form Health Survey Physical Health summary measure. SF-36 MH: Short Form Health Survey Mental Health scale.
aEstimated from
reported P value.
b> 4% SaO2 dip rate per hour in algorithm-determined CPAP arm.
cMedian in algorithm-determined CPAP arm.
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4Overall  (I2 = 18%, P = 0.22)
AHI ≥ 30 events/hr
Konermann (1998)
Senn A (2003)
Subtotal  (I2 = 66%, P = 0.019)
To (2008)
Study (Year)
No data
Patruno (2007)
AHI ≥ 10 events/hr
Resta (2004)
Nolan (2007)
Fietze (2007)
Teschler (2000)
Subtotal  (I2 = 21%, P = 0.26)
Senn B (2003)
Hudgel (2000)
Planes (2003)
AHI ≥ 20 events/hr
Noseda (2004)
Vennelle (2010)
Galetke (2008)
Subtotal  (I2 = 6%, P = 0.38)
Marrone (2004)
Minimum AHI
AHI ≥ 5 events/hr
d'Ortho (2000)
Randerath (2001)
AHI ≥ 15 events/hr
Nussbaumer (2006)
Meurice (2007)
Damjanovic (2009)
Hukins (2004)
Subtotal  (I2 = 0%, P = 0.77)
Hussain (2004)
Massie (2003)
Subtotal  (I2 = 1%, P = 0.39)
0.18 (0.05, 0.31)
0.30 (-0.59, 1.19)
-0.10 (-0.69, 0.49)
0.03 (-0.57, 0.63)
0.70 (0.17, 1.23)
Difference (95% CI)
0.20 (-0.25, 0.65)
-0.10 (-1.12, 0.92)
0.00 (-0.59, 0.59)
0.80 (-0.02, 1.62)
0.20 (-0.70, 1.10)
0.28 (0.00, 0.55)
-0.10 (-0.69, 0.49)
0.50 (0.02, 0.98)
-0.80 (-1.62, 0.02)
-0.20 (-0.89, 0.49)
0.20 (0.00, 0.40)
-0.01 (-0.82, 0.80)
0.04 (-0.20, 0.29)
0.50 (-0.26, 1.26)
-0.60 (-1.52, 0.32)
0.00 (-0.44, 0.44)
0.30 (-0.29, 0.89)
-0.40 (-1.28, 0.48)
0.10 (-0.88, 1.08)
0.19 (-0.06, 0.44)
0.13 (-0.20, 0.45)
0.60 (-0.84, 2.04)
0.58 (0.17, 0.99)
0.28 (0.10, 0.46)
3-6
1
2
Months
3
1
2
1.5
2
1
3
2
2
1.5
2
1
2
1.5
1
6
9
1.5
1
1.5
25
29
41
APAP
15
10
29
20
10
29
14
16
24
181
20
22
N
25
52
30
15
34
46
10
44
23
29
41
Fixed
16
10
29
21
10
29
19
14
24
181
20
22
N
25
52
30
14
44
46
10
44
38
46
54
AHI
46
47
15
42
53
46
30
59
51
33
33
68
Base
58
35
41
55
44
56
47
5.7
5.6
3.7
Fixed
6
5.3
4.9
4.2
6.1
5.6
5.5
5.3
5.5
4.2
6.4
4.4
Compliance
4.7
5.3
4.8
6.1
5.1
4.9
3.7
4.5
B
B
B
Quality
C
C
B
C
C
B
C
C
B
A
C
C
B
B
B
B
B
B
C
B
2
P=0.006
Favors Fixed   Favors APAP 
0.0 -2.0 -1.5 -1.0 -0.5 0.5 1.0 1.5 2.0
Hours/Night
Figure 2 CPAP compliance (hour/night) with APAP versus fixed CPAP: meta-analysis, with subgroup analyses by minimum AHI
threshold. Estimates and 95% CIs by study subgrouped by minimum AHI threshold used in each study. The overall random effects model
meta-analysis is displayed by the black diamond, which spans the width of the 95% CI. Each subgroup meta-analysis, by AHI threshold, is shown
by the open diamonds. Grey boxes are proportional to the weight of each study in the overall meta-analysis. For each meta-analysis the I
2
statistic and the P value for heterogeneity is displayed. The P value for the summary estimate is displayed next to the black diamond. Note that
studies favoring APAP are to the right of the vertical 0 line. Base AHI: baseline apnea-hypopnea index (events/hour) in fixed CPAP group;
compliance fixed: compliance (hour/night) in fixed CPAP group; fixed: fixed CPAP.
Overall  (I2 = 0%, P = 0.63)
Minimum AHI
Hussain (2004)
Meurice (2007)
AHI ≥ 20 events/hr
AHI ≥ 15 events/hr
Resta (2004)
Fietze (2007)
Planes (2003)
Randerath (2001)
Konermann (1998)
Nolan (2007)
d'Ortho (2000)
Subtotal  (I2 = 0%, P = 0.80)
Patruno (2007)
Damjanovic (2009)
Galetke (2008)
Nussbaumer (2006)
Teschler (2000)
Subtotal  (I2 = 0%, P = 0.82)
Senn B (2003)
Senn A (2003)
Subtotal  (I2 = 46%, P = 0.16)
Massie (2003)
AHI ≥ 30 events/hr
Study (Year)
Subtotal  (I2 = 0%, P = 0.78)
AHI ≥ 10 events/hr
AHI ≥ 5 events/hr
0.25 (-0.16, 0.66)
3.50 (-1.02, 8.02)
2.60 (-8.87, 14.07)
-2.80 (-12.95, 7.35)
0.50 (-1.19, 2.19)
0.70 (-10.06, 11.46)
0.70 (-0.88, 2.28)
1.60 (-4.52, 7.72)
-0.80 (-1.89, 0.29)
0.90 (-2.44, 4.24)
0.74 (0.01, 1.47)
2.70 (-7.01, 12.41)
1.80 (-7.14, 10.74)
1.00 (-0.45, 2.45)
-0.80 (-3.30, 1.70)
0.30 (-0.29, 0.89)
0.32 (-0.26, 0.90)
2.40 (-0.34, 5.14)
0.70 (-1.26, 2.66)
0.64 (-2.69, 3.96)
-1.10 (-2.89, 0.69)
Difference (95% CI)
-0.05 (-6.26, 6.16)
1
6
1
1.5
2
1.5
3-6
2
2
3
3
2
1
2
1
1
1.5
Months
N
10
15
10
20
16
52
25
29
25
15
46
20
30
20
29
29
44
APAP
N
10
14
10
21
14
52
23
29
25
16
46
20
30
20
29
29
44
Fixed
Base
47
56
45
40
61
35
38
15
58
46
46
33
41
53
46
46
AHI
C
B
C
C
C
B
B
C
B
C
B
C
B
C
B
B
B
Quality
P=0.23
Favors APAP Favors Fixed
0.0 -10.0 -5.0 5.0 10.0 15.0
Events/Hour
Figure 3 AHI (events/hour) with APAP versus fixed CPAP: meta-analysis, with subgroup analyses by minimum AHI threshold.S e e
Figure 2 legend. Note that studies favoring APAP are to the left of the vertical 0 line. Senn A and Senn B were comparisons of two different
APAP devices versus fixed CPAP reported in the same study. Base AHI: baseline apnea-hypopnea index (events/hour) in fixed CPAP group; fixed:
fixed CPAP.
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Page 19 of 24Overall  (I2 = 9%, P = 0.34)
Massie (2003)
Minimum AHI
To (2008)
Planes (2003)
Subtotal  (I2 = 0%, P = 0.59)
AHI ≥ 20 events/hr
Subtotal  (I2 = 0%, P = 0.48)
Vennelle (2010)
Study (Year)
Noseda (2004)
Hussain (2004)
Marrone (2004)
No data
Subtotal  (I2 = 0%, P = 0.56)
Subtotal  (I2 = 18%, P = 0.30)
Nussbaumer (2006)
AHI ≥ 30 events/hr
Hudgel (2000)
Randerath (2001)
Series A (1997)
Damjanovic (2009)
Galetke (2008)
Series B (1997)
AHI ≥ 10 events/hr
Senn B (2003)
Senn A (2003)
Meurice (2007)
Nolan (2007)
Resta (2004)
AHI ≥ 15 events/hr
AHI ≥ 5 events/hr
d'Ortho (2000)
-0.48 (-0.81, -0.15)
-1.00 (-2.06, 0.06)
0.00 (-1.76, 1.76)
-0.90 (-3.72, 1.92)
-0.54 (-0.95, -0.13)
-0.99 (-1.93, -0.05)
-0.50 (-0.95, -0.05)
Difference (95% CI)
-1.00 (-1.76, -0.24)
1.40 (-2.20, 5.00)
-1.00 (-2.40, 0.40)
0.80 (-0.75, 2.34)
-0.24 (-0.91, 0.44)
0.00 (-1.35, 1.35)
1.00 (-0.96, 2.96)
-1.00 (-2.26, 0.26)
-0.80 (-4.29, 2.69)
-0.30 (-2.32, 1.72)
-1.70 (-3.76, 0.36)
1.80 (-1.79, 5.39)
-0.20 (-1.68, 1.28)
0.80 (-0.49, 2.09)
-3.00 (-6.44, 0.44)
0.90 (-0.99, 2.79)
-2.60 (-5.84, 0.64)
0.10 (-1.93, 2.13)
1.5
2
2
1.5
Months
2
1
1
1
3
1.5
0.75
3
2
0.75
1
1
6
2
1
2
44
N
41
16
181
APAP
24
10
22
30
39
52
12
46
20
12
29
29
15
29
10
25
44
N
41
14
181
Fixed
24
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22
30
39
52
12
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12
29
29
14
29
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Base
54
61
33
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47
68
41
30
35
50
46
33
50
46
46
56
15
45
58
Base
13.4
14.7
14
ESS
10.7
11.1
16.3
12.7
16
11.1
17
9.3
10.3
13.5
14.2
14.2
10.6
12.3
12
12.7
B
B
C
A
Quality
B
C
C
B
C
B
C
B
C
C
B
B
B
B
C
B
P=0.005
Favors APAP   Favors Fixed 
0.0 -7.0 -5.0 -3.0 -1.0 1.0 3.0 5.0 7.0
Units
Figure 4 ESS with APAP versus fixed CPAP: meta-analysis, with subgroup analyses by minimum AHI threshold. See Figure 2 legend.
Note that studies favoring APAP are to the left of the vertical 0 line. Senn A and Senn B, and Sériès A and Sériès B, were comparisons of two
different APAP devices versus fixed CPAP reported in the same study, respectively. Base AHI: baseline apnea-hypopnea index (events/hour) in
fixed CPAP group; base ESS: baseline Epworth Sleepiness Scale (no units) in fixed CPAP group; fixed: fixed CPAP.
Overall  (I2 = 23%, P = 0.24)
Hussain (2004)
d'Ortho (2000)
Subtotal  (I2 = 49%, P = 0.14)
AHI ≥ 30 events/hr
Subtotal  (I2 = 0%, P = 0.78)
AHI ≥ 10 events/hr
Nolan (2007)
AHI ≥ 20 events/hr
Damjanovic (2009)
Konermann (1998)
Subtotal  (I2 = 0%, P = 0.64)
AHI ≥ 15 events/hr
Planes (2003)
Resta (2004)
Randerath (2001)
Study (Year)
Galetke (2008)
AHI ≥ 5 events/hr
Minimum AHI
-0.85 (-2.25, 0.54)
1.00 (-2.50, 4.50)
1.80 (-1.53, 5.13)
0.01 (-2.32, 2.34)
0.80 (-2.39, 3.98)
-3.00 (-5.71, -0.29)
-0.20 (-7.92, 7.52)
-3.30 (-6.59, -0.01)
1.36 (-5.18, 7.89)
3.30 (-7.14, 13.74)
0.10 (-8.29, 8.49)
-1.70 (-3.70, 0.30)
Difference (95% CI)
1.00 (-2.52, 4.52)
1
2
2
3
3-6
2
1
1.5
Months
2
10
25
29
46
25
16
10
52
APAP
20
N
10
25
29
46
23
14
10
52
Fixed
20
N
47
58
15
46
38
61
45
35
AHI
33
Base
17.3
45.6
16
34.5
13.3
48.5
43.1
34
AI
12.6
Base
C
B
B
B
B
C
C
B
Quality
C
P=0.231
Favors APAP   Favors Fixed 
0.0 -10.0 -5.0 5.0 10.0
Events/Hour
Figure 5 Arousal index (events/hour) with APAP versus fixed CPAP: meta-analysis, with subgroup analyses by minimum AHI
threshold. See Figure 2 legend. Note that studies favoring APAP are to the left of the vertical 0 line. Senn A and Senn B were comparisons of
two different APAP devices versus fixed CPAP reported in the same study. Base AHI: baseline apnea-hypopnea index (events/hour) in fixed CPAP
group; Base AI: baseline arousal index (events/hour) in fixed CPAP group; fixed = fixed CPAP.
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Page 20 of 24significant difference of 11 minutes per night also favor-
ing APAP compared to fixed CPAP. The clinical signifi-
cance of these reported improvements in ESS and
compliance, however, is unclear. The two types of
devices were found to result in similar changes from
baseline in AHI, quality of life and most other sleep
study measures. However, there is also evidence that
minimum oxygen saturation improves more with CPAP
than with APAP by about 1%. Evidence is limited
regarding the relative effect of fixed CPAP and APAP
on blood pressure. There were no data on objective clin-
ical outcomes.
T h ee t i o l o g ya n ds e v e r i t yo fO S Av a r i e sw i d e l ya c r o s s
patients, as do patients’ symptoms and their ability to
tolerate or consistently use treatments. CPAP, specifi-
cally, can be cumbersome and uncomfortable to use;
therefore, it is of particular importance to identify which
subgroups of patients may benefit most from which spe-
cific treatments to maximize the effectiveness of inter-
vention. Our subgroup meta-analyses based on different
minimum AHI thresholds to define OSA failed to
demonstrate any difference in effectiveness between
APAP and CPAP for all outcomes. Higher AHI is used
as a marker for more severe disease [35] and is asso-
ciated with greater mortality [1,36-38]; however, our
power to find any differences based on baseline AHI
was low, particularly since the study eligibility categories
overlapped. Even if we had found a difference, it would
at best be hypothesis-generating and would need to be
confirmed in a primary study. But we found no study
that directly analyzed any subgroup of patients who may
particularly benefit from a given treatment. It should be
noted that experts have opined that APAP may be used
in the setting of failed fixed CPAP (CD, personal com-
munication), although we are not aware of a study in
such a setting.
Despite the addition of newer studies in our meta-ana-
lyses, our findings differ e dl i t t l ef r o mt h o s eo fa
Cochrane meta-analysis reported in 2009, which
reviewed 30 randomized trials enrolling 1,136 patients
in total (the Cochrane review had a larger number of
RCTs because it included results from posters and con-
ference proceedings) [4]. The Cochrane review segre-
gated its analysis by study design into cross-over and
parallel design studies but did not provide an aggregate
analysis combining both types of study design. In that
meta-analysis, a statistically significant difference in
compliance of 12.6 minutes per night (95% CI, 4.8 to 21
minutes increase) was found in favor of APAP in cross-
over studies, but no significant difference in parallel
design studies. It also reported a statistically significant
decrease in ESS of 0.64 points (95% CI, 0.12 to 1.16
point decrease) in favor of APAP in cross-over studies,
but no significant difference in parallel design studies.
We reported similar findings for the two study designs
in our full technical review [6].
Overall  (I2 = 0%, P = 0.70)
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Konermann (1998)
Subtotal  (I2 = 0%, P = 0.90)
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Meurice (2007)
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-1.30 (-2.16, -0.44)
-3.90 (-7.26, -0.54)
4.80 (-7.38, 16.98)
-1.20 (-2.12, -0.28)
0.90 (-7.37, 9.17)
-4.40 (-11.80, 3.00)
-1.80 (-3.82, 0.22)
Difference (95% CI)
-1.20 (-6.51, 4.12)
-1.00 (-2.09, 0.09)
-1.40 (-4.70, 1.90)
1.10 (-4.86, 7.06)
0.51 (-4.96, 5.97)
0.20 (-7.07, 7.47)
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Figure 6 Minimum oxygen saturation (%) with APAP versus fixed CPAP: meta-analysis, with subgroup analyses by minimum AHI
threshold. See Figure 2 legend. Note that studies favoring APAP are to the left of the vertical 0 line. Senn A and Senn B were comparisons of
two different APAP devices versus fixed CPAP reported in the same study. Base AHI: baseline apnea-hypopnea index (events/hour) in fixed CPAP
group; Base min O2: baseline minimum oxygen saturation (%) in fixed CPAP group; fixed: fixed CPAP.
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Page 21 of 24Follow-up durations in the studies reviewed tended
to be short, in the order of weeks to a few months,
and are clearly insufficient for the appraisal of the
treatment of a life-long disease whose clinical sequelae
may take decades to develop. Study dropout rates were
also frequently very high, particularly given the short
duration of follow-up. In some studies, up to 40% of
participants were lost to follow-up within weeks. The
ability to meaningfully interpret the findings from
these studies is clearly diminished. Other frequent
methodological problems included incomplete report-
ing and/or inadequate analyses. In particular, relatively
few studies provided the net differences between inter-
ventions (in parallel design studies) or the difference
between final values with appropriate adjustments for
correlation (in cross-over studies) with their confi-
dence intervals and P values. Thus for the large major-
ity of studies, we had to estimate the confidence
intervals of the differences between interventions. We
also did not search for unpublished and non-English
language studies.
Conclusions
APAP and CPAP were similar in affecting relatively
short-term changes in AHI, quality of life, and most
other sleep study measures in the treatment of patients
with moderate to severe OSA but without significant
comorbidities. APAP, however, did reduce sleepiness by
approximately 0.5 ESS points more than fixed CPAP.
Patients who received APAP also had objectively mea-
sured compliance of 11 minutes per night more than
those who received fixed CPAP. We surmise that the
clinical significance of these reported improvements in
ESS and compliance is marginal at best. It is doubtful
that additional short-term trials comparing APAP and
CPAP to examine these measures will substantially alter
these results. However, longer-term and larger trials that
evaluate clinical outcomes, such as cardiovascular
events, and directly estimate differential effects in differ-
ent sub-populations may be of value. Furthermore, the
current trial evidence is limited to patients newly diag-
nosed with sleep apnea or who are otherwise naïve to
CPAP; thus, future trials of patients who had previously
used CPAP may be of value. For now, based on the
available data from experimental studies on short-term
effects only, the decision to use APAP versus CPAP may
well depend on individual patient preferences, specific
reasons for non-compliance, costs and other practical
considerations that clinicians and patients will need to
assess on an individual basis.
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AHI: apnea-hypopnea index; AHRQ: Agency for Healthcare Research and
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Table 11 Strength of evidence of APAP versus CPAP
Outcomes Number
of trials
Total
number
Trials with data
for Meta-
analysis
Meta-analysis results
comparing APAP with
CPAP
Favors Strength
of
evidence
Clinical outcomes (death,
cardiovascular events and
others)
0 0 0 N/A Insufficient
Compliance 24 1008 22 0.18 hours (95% CI 0.05
to 0.31; P = 0.006)
APAP Moderate
Apnea-Hypopnea Index 16 548 16 0.25 events/hour (95%
CI -0.16 to 0.66; NS)
No difference Moderate
Epworth Sleepiness Scale 22 954 18 -0.48 (95% CI -0.81 to
-0.15; P = 0.005)
APAP Moderate
Arousal Index 10 356 9 -0.85 events/hour (95%
CI -2.2 to 0.5; NS)
No difference Moderate
Minimum O2 saturation 9 258 9 -1.3% (95% CI -2.2 to
-0.4; P = 0.003)
CPAP Moderate
Sleep efficiency 3 126 0 No difference Insufficient
Rapid eye movement sleep 9 273 0 No difference Moderate
Slow wave sleep 8 243 0 No difference in seven trials; one trial
favored APAP
Moderate
Quality of life 9 509 0 No difference in eight trials; one trial
favored APAP
Moderate
Blood pressure 3 149 0 No difference in two trials; one trial
favored CPAP (decrease in diastolic
blood pressure)
Insufficient
APAP: auto-titrating CPAP; CPAP: continuous positive airway pressure; N/A: not applicable; NS: non-significant.
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